An Observational Study of Patients With Chronic Liver Disease
Launched by TARGET PHARMASOLUTIONS, INC. · Feb 15, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Disease Cohort
- • •Adult\* patients at the time of enrollment with a diagnosis of CLD/cirrhosis by ICD-10 code in the EHR interface
- • Engaged Cohort
- • Adult\* patients diagnosed and managed for CLD/cirrhosis invited to participate
- • Ability to provide written informed consent
- Exclusion Criteria:
- • Disease Cohort
- • Death
- • Manual removal (sponsor or site request)
- • No EHR interface encounter \> 3 years.
- • Engaged Cohort
- • Patient expressed desire to withdraw consent to complete PROs
- • Failure to complete PROs within 24 weeks of initial invitation
- • Greater than 24 months lapse of survey completion after baseline surveys completed
- • Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort.
About Target Pharmasolutions, Inc.
Target Pharmasolutions, Inc. is a leading clinical trial sponsor dedicated to advancing pharmaceutical research and development. With a focus on innovative solutions, the company specializes in providing comprehensive clinical trial management services that enhance the efficiency and effectiveness of drug development. Target Pharmasolutions leverages cutting-edge technology and a team of experienced professionals to ensure regulatory compliance and optimize patient engagement, ultimately facilitating the successful delivery of new therapies to market. Committed to quality and integrity, the company partners with biopharmaceutical organizations to support their clinical goals and drive transformative outcomes in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
New York, New York, United States
Houston, Texas, United States
Redwood City, California, United States
Dallas, Texas, United States
New York, New York, United States
Washington, District Of Columbia, United States
Charlotte, North Carolina, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials